Abstract: Objective To investigate the diagnostic value of portal vain by ultrasonography and serum matrix metalloproteinase-2 （MMP-2） and tissue inhibitor of metalloproteinase-2（TIMP-2） in patients with chronic hepatitis B （CHB）.Methods Forty-three patients with CHB and 40 healthy controls were enrolled in our hospital between May 2014 and May 2018,and all patients underwent liver biopsy for liver fibrosis staging. B-ultrasound was performed in all subjects,and the width of portal vein, the width of the splenic vein,and the thickness of the spleen were measured. Serum MMP-2 and TIMP-2 levels as well as hyaluronic acid （HA）,laminin （LN）,type IV collagen（IV-C） and III procollagen amino terminal peptide （P III P） were assayed.Results Liver biopsy results showed that there were 13 patients with S0-S1,11 patients with S2,14 patients with S3,and 5 patients with S4;From S2 to S4 with the increasing degree of liver fibrosis,the portal vein width,splenic vein width and spleen thickness increased gradually,and the differences between patients with different liver fibrosis was statistically significant（P<0.05）;Serum MMP-2 levels in patients with S0-1,S2,S3 and S4 were（291.5±35.3） mg/L,（357.7±32.5） mg/L,（446.8±47.1） mg/L and （595.3±85.4） mg/L,and serum TIMP-2 levels were （154.3±28.6）mg/L,（210.7±24.1） mg/L,（255.7±31.9） mg/L and （302.5±74.3） mg/L,significantly higher than（246.5±32.1） mg/L and （126.5±20.1） mg/L（P<0.05） in healthy persons;serum HA,LN,IV-C and P III P levels in patients with significant liver fibrosis were higher than those in healthy control （P<0.05）. Conclusion The examination of portal vain parameters by ultrasonography and serum liver fibrosis determination might help predict the intrahepatic liver fibrosis in patients with CHB.

Key words: Hepatitis B, Ultrasonography, Mmatrix metalloproteinase-2, Tissue inhibitor of metalloproteinase-2